Revisiting ribonucleotide reductase as a target to enhance radiation and chemotherapy anti-tumor activity.
Sznol
Mario
M
Vion Pharmaceuticals, Inc., New Haven, Connecticut 06511, USA. msznol@vionpharm.com
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002277:Carcinoma / Q000188:drug therapy / Q000201:enzymology* / Q000532:radiotherapy; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D004260:DNA Repair / Q000187:drug effects / Q000528:radiation effects; D004273:DNA, Neoplasm / Q000187:drug effects / Q000528:radiation effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000528:radiation effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology*; D009303:Nasopharyngeal Neoplasms / Q000201:enzymology; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D013937:Thymidine Kinase / Q000378:metabolism; D015854:Up-Regulation
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D012264:Ribonucleotide Reductases; D013937:Thymidine Kinase; D006918:Hydroxyurea